Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL ASPIRIN AND CODEINE PHOSPHATE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL ASPIRIN AND CODEINE PHOSPHATE versus WESTADONE.
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting skeletal muscle relaxant that produces muscle relaxation by blocking interneuronal activity in the descending reticular formation and spinal cord, likely acting as a prodrug to meprobamate, which enhances GABA activity at GABA-A receptors. Aspirin irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting prostaglandin synthesis involved in pain, fever, and inflammation. Codeine phosphate is an opioid agonist with weak affinity for mu-opioid receptors; it is primarily metabolized to morphine via CYP2D6, which mediates its analgesic effects.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1-2 tablets (carisoprodol 200 mg, aspirin 325 mg, codeine phosphate 16 mg) orally every 6 hours as needed for pain, maximum 6 tablets per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Carisoprodol: ~2 hours (range 1-3 h). Aspirin: ~2-3 hours for salicylate (low dose), up to 15-30 h at high doses or overdose (zero-order kinetics). Codeine: ~3-4 hours (range 2.5-4.5 h). Clinically, repeated doses may lead to accumulation of salicylate due to saturable metabolism.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Carisoprodol: ~60% renal as metabolites, <1% unchanged. Aspirin: renal excretion of salicylate and metabolites (75% as salicyluric acid, 10% as glucuronides, 10% as free salicylate). Codeine: ~90% renal as conjugates, ~10% unchanged, ~10% as morphine and norcodeine.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist